New drug combo shows promise in advanced melanoma trial

NCT ID NCT04109456

First seen Jan 17, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This early-stage trial tested the safety of a new drug called IN10018, given alone or with other medicines, in 51 adults with advanced melanoma that had spread. The goal was to see if the treatment was safe and tolerable, not to cure the disease. Participants had either uveal melanoma or a specific genetic type of skin melanoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • MD Anderson

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • St Vincent Hospital Sydney

    Sydney, New South Wales, Australia

  • Sylvester Comprehensive Cancer Center.

    Miami, Florida, 33136, United States

  • The Alfred Hospital

    Melbourne, Victoria, Australia

Conditions

Explore the condition pages connected to this study.